|Condition:||Diabetes Mellitus Type 2|
|Keywords:||Insulin degludec, long-ating insulin anaogues, long acting insulin analogues|
Please select a BNF chapter code to go to the formulary.
060101 - Insulin
|Date||Committee Name||Narrative||Traffic Light Status Traffic Light Status|
|05 April 2017||Prescribing Clinical Network||
See narrative below from Sep 2016.
The Sep 2016 policy statement has been subject to a minor change and an amended statement is available below.
|07 September 2016||Prescribing Clinical Network||
The PCN recommends the use of Insulin Degludec (Tresiba®) in type II diabetes in line with the policy statement (217-2016) below. Insulin Degludec (Tresiba®) in type II diabetes will be considered as BLUE (without an information sheet) on the traffic light system
Important - Insulin degludec is available in strengths of 100units/mL and 200units/mL - ensure correct strength is prescribed and dispensed - see MHRA Safety Update (below) for key points and practical information.
|Type:||Document (click to view)||Review Date|
|Policy Statement||Degludec for Type 2 diabetes - Policy statement 217-2016 - amended Apr 2017||April 2020|
|Information||Degludec - MHRA drug safety update - April 2013|
|Information||Degludec for Type 2 diabetes - Change in Traffic Light status application - Sep 2016|
|Relevant for the
|Document (click to view)||Type:||Review Date|
|Surrey Downs CCG||SDCCG - Insulin initiation in Type 2 Diabetes Guidelines - Sep 2014||Guidelines (Local)||October 2015|